Science & Enterprise subscription

Follow us on Twitter

  • When even PhRMA doesn't want to be a Trump campaign prop ... A Deal on Drug Prices Undone by White House Insistence… https://t.co/JjdVxOTVV6
    about 15 hours ago
  • A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $… https://t.co/D8kwt0ng5X
    about 16 hours ago
  • New post on Science and Enterprise: Mental Health Drug Company Raises $127.5M in IPO https://t.co/39Xea7VQpV #Science #Business
    about 16 hours ago
  • A test for SARS-CoV-2 viruses is shown in field tests to return diagnostic results in 90 minutes with accuracy comp… https://t.co/EuQIPTsL57
    about 20 hours ago
  • New post on Science and Enterprise: Point-of-Care Covid-19 Diagnostic Shows High Accuracy https://t.co/4l3pGrHx2o #Science #Business
    about 20 hours ago

Please share Science & Enterprise

Mental Health Drug Company Raises $127.5M in IPO

NASDAQ share price display

A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer. . . . → Read More: Mental Health Drug Company Raises $127.5M in IPO

Point-of-Care Covid-19 Diagnostic Shows High Accuracy

CovidNudge unit

A test for SARS-CoV-2 viruses in humans is shown in field tests to return diagnostic results in 90 minutes with accuracy comparable to the gold-standard RT-PCR test. . . . → Read More: Point-of-Care Covid-19 Diagnostic Shows High Accuracy

Wearable Device Shown to Relieve Migraine Pain

Brain activity graphic

Evidence collected from electronic neuro-stimulation devices shows for most people the wearable systems relieve migraine pain without other drugs. . . . → Read More: Wearable Device Shown to Relieve Migraine Pain

Biotechs Partner on Gene-Editing Cystic Fibrosis Therapy

lung illustration

Two biotechnology companies are adding to their current collaboration to develop delivery techniques for gene-editing treatments for cystic fibrosis. . . . → Read More: Biotechs Partner on Gene-Editing Cystic Fibrosis Therapy

Early Trial Results Show Antibody Treating Covid-19

SARS-Cov-2 virus

First results from a clinical trial testing an experimental synthetic antibody, show patients receiving the therapy at a specific dosage, cleared their SARS-CoV-2 viruses within 11 days. . . . → Read More: Early Trial Results Show Antibody Treating Covid-19

Precision Cancer Therapy Start-Up Gains $110M in Early Funds

Human T-cell

A company creating cancer therapies with individualized engineered T-cells is raising $110 million in its first venture funding round. . . . → Read More: Precision Cancer Therapy Start-Up Gains $110M in Early Funds

Gilead Acquires Cancer Therapy Biotech for $21B

Investment graphic

Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion. . . . → Read More: Gilead Acquires Cancer Therapy Biotech for $21B

NIH Trials Testing Covid-19 Blood Clot Therapies

Heart, circulation system

National Institutes of Health is starting two clinical trials testing a number of blood thinning treatments for people with blood clots from Covid-19 infections. . . . → Read More: NIH Trials Testing Covid-19 Blood Clot Therapies

Antibody Discovery Company Forms, Partners on Covid-19

Network pointer

A new enterprise formed to discover human therapeutic antibodies is partnering with a synthetic biology company to discover Covid-19 antibody treatments. . . . → Read More: Antibody Discovery Company Forms, Partners on Covid-19

Small Biz Grant Funds Covid-19 Disinfectant Spray

Spray bottle

A Florida start-up company is developing a fast-acting disinfectant spray that dries on contact, yet still kills Covid-19 viruses on surfaces. . . . → Read More: Small Biz Grant Funds Covid-19 Disinfectant Spray